These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9288436)

  • 21. Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys.
    Harrigan SE; Downs DA
    NIDA Res Monogr; 1981; 28():77-92. PubMed ID: 6791015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
    Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
    Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma naltrexone during opioid detoxification.
    McDonald T; Berkowitz R; Hoffman WE
    J Addict Dis; 2000; 19(4):59-64. PubMed ID: 11110065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A predictive study of obsessive-compulsive disorder response to clomipramine.
    Alarcon RD; Libb JW; Spitler D
    J Clin Psychopharmacol; 1993 Jun; 13(3):210-3. PubMed ID: 8354737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid dependence.
    Praveen KT; Law F; O'Shea J; Melichar J
    Am Fam Physician; 2012 Sep; 86(6):565-6. PubMed ID: 23062049
    [No Abstract]   [Full Text] [Related]  

  • 27. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains.
    Terner JM; Barrett AC; Lomas LM; Negus SS; Picker MJ
    Pain; 2006 May; 122(1-2):90-101. PubMed ID: 16527399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A different opinion regarding the use of opiate antagonists in PTSD: comments on "An unusual reaction to opioid blockade with naltrexone in a case of post-traumatic stress disorder".
    Glover H
    J Trauma Stress; 1995 Jul; 8(3):483-9. PubMed ID: 7582612
    [No Abstract]   [Full Text] [Related]  

  • 29. Dissociable effects of ultralow-dose naltrexone on tolerance to the antinociceptive and cataleptic effects of morphine.
    Tuerke KJ; Beninger RJ; Paquette JJ; Olmstead MC
    Behav Pharmacol; 2011 Sep; 22(5-6):558-63. PubMed ID: 21555938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
    Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
    Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discriminative stimulus effects of naltrexone after a single dose of morphine in the rat.
    Easterling KW; Holtzman SG
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1269-77. PubMed ID: 10027868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N; Sun S; Johnson F; Stauffer J
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride.
    Knesevich JW
    Am J Psychiatry; 1982 Mar; 139(3):364-5. PubMed ID: 7058953
    [No Abstract]   [Full Text] [Related]  

  • 35. Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade.
    Bashaw ED; Kaiko RF; Grandy RP; Reder RF; Goldenheim PD
    Int J Clin Pharmacol Ther; 1995 Sep; 33(9):524-9. PubMed ID: 8520812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability.
    Turel AP; Oh KH; Zagon IS; McLaughlin PJ
    J Clin Psychopharmacol; 2015 Oct; 35(5):609-11. PubMed ID: 26203498
    [No Abstract]   [Full Text] [Related]  

  • 37. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
    Katz N; Hale M; Morris D; Stauffer J
    Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study of reversibly inactivated lipases for use in a morphine-triggered naltrexone delivery system.
    Nakayama GR; Roskos KV; Fritzinger BK; Heller J
    J Biomed Mater Res; 1995 Nov; 29(11):1389-96. PubMed ID: 8582907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Injectable extended-release naltrexone for opioid dependence.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Aug; 378(9792):665; author reply 666. PubMed ID: 21856477
    [No Abstract]   [Full Text] [Related]  

  • 40. Concerns about injectable naltrexone for opioid dependence.
    Wolfe D; Carrieri MP; Dasgupta N; Wodak A; Newman R; Bruce RD
    Lancet; 2011 Apr; 377(9776):1468-70. PubMed ID: 21529930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.